Please login to the form below

Not currently logged in
Email:
Password:

Nanobiotix strengthens US leadership team

Dr Mihail Obrocea and Noël Kurdi join the nanomedicine company

Nanobiotix Dr Mihail ObroceaFrench oncology specialist Nanobiotix has strengthened its US leadership team with the appointments of Dr Mihail Obrocea and Noël Kurdi.

Dr Obrocea (pictured right) joins Nanobiotix as head of US clinical development, bringing 20 years of clinical research leadership to the role.

Most recently, Dr Obrocea was AbbVie Biotherapeutics' project director and oncology clinical lead, overseeing a number of trials in oncology and hematology.

He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

Nanobiotix Noel KurdiMeanwhile, Kurdi (pictured left) becomes director of investor relations at Nanobiotix, moving from the Trout Group where she served as a senior associate.

Kurdi has previously worked in institutional equity sales and research at Brean Capital, and business development and investor relations at AIG Investments in New York.

7th October 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...